ARCHIVES

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

This article is from The Cancer Letter archive.

Vol. 33 No. 16 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977

In Brief: Some Cancer Centers Funded At “Recommended” Levels For Fiscal 1981, But There Was A Catch

October 30, 1981

NCI Cooperative Group, Cancer Center Trials Listed

January 30, 2009

FDA Approves Xeloda For Breast Cancer Treatment.

September 28, 2001

Better Access Key To Higher Survival For African-Americans With Colon Cancer

August 30, 2002

More Than 3,000 Letters If Intent Sent To army For Breast Programs

September 10, 1993